Harris Joshua D, Griesser Michael J, Copelan Alex, Jones Grant L
Department of Orthopaedics, The Ohio State University Sports Medicine Center, OH, Columbus.
Int J Shoulder Surg. 2011 Apr;5(2):31-7. doi: 10.4103/0973-6042.83194.
Sodium hyaluronate injection into the glenohumeral joint is a treatment option in the management of adhesive capsulitis of the shoulder. We hypothesized that a systematic review would demonstrate that intra-articular sodium hyaluronate injections would result in significant improvements in passive range-of-motion, shoulder and general clinical outcome measures, and pain scales at short- and mid-term follow-up. Multiple medical databases were searched for levels I-IV evidence with a priori defined specific inclusion and exclusion study criteria. Clinical outcome measures used included Constant score, VAS pain scores, Cho functional scores, JOA scores, and range-of-motion measurements. Seven studies were included (four Level I and three Level IV; 292 subjects, 297 shoulders). Mean subject age was 59.1 years and mean pre-treatment duration of symptoms was 7.3 months. 140 subjects underwent one or multiple hyaluronate injections (120 glenohumeral joint; 20 subacromial bursa). Clinical follow-up was mean 9.0 weeks. Sodium hyaluronate injection into the glenohumeral joint has significantly improved shoulder range-of-motion, constant scores, and pain at short-term follow-up following treatment of adhesive capsulitis. Isolated intra-articular hyaluronate injection has significantly better constant scores than control. Isolated intra-articular hyaluronate injection has equivalent clinical outcomes and range-of-motion compared to intra-articular corticosteroid injection. Intra-articular hyaluronate injection was safe, with no reported complications within the studies in this review. Sodium hyaluronate injection into the glenohumeral joint is a safe, effective treatment in the management of adhesive capsulitis of the shoulder. Short-term evidence indicates that clinical outcomes are better than control and equivalent to intra-articular corticosteroid injection.
向盂肱关节注射透明质酸钠是治疗肩周炎的一种选择。我们假设系统评价将表明,关节内注射透明质酸钠会在短期和中期随访中使被动活动范围、肩部及总体临床结局指标和疼痛量表评分得到显著改善。我们在多个医学数据库中检索了I-IV级证据,并预先定义了特定的纳入和排除研究标准。所使用的临床结局指标包括Constant评分、视觉模拟评分法(VAS)疼痛评分、Cho功能评分、日本骨科学会(JOA)评分和活动范围测量。纳入了7项研究(4项I级和3项IV级;292名受试者,297个肩部)。受试者的平均年龄为59.1岁,症状的平均治疗前持续时间为7.3个月。140名受试者接受了一次或多次透明质酸钠注射(120次盂肱关节注射;20次肩峰下囊注射)。临床随访平均为9.0周。在肩周炎治疗后的短期随访中,向盂肱关节注射透明质酸钠显著改善了肩部活动范围、Constant评分和疼痛。单纯关节内注射透明质酸钠的Constant评分显著优于对照组。与关节内注射皮质类固醇相比,单纯关节内注射透明质酸钠具有相当的临床结局和活动范围。关节内注射透明质酸钠是安全的,在本综述的研究中未报告并发症。向盂肱关节注射透明质酸钠是治疗肩周炎的一种安全、有效的方法。短期证据表明,临床结局优于对照组,且与关节内注射皮质类固醇相当。